옵션 체인은 다양한 행사가격과 만기일에 대한 의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 에 대한 시장 심리를 평가합니다..

 (NASDAQ:FFIE) 주식, 옵션 체인

A Tesla Car Costs Less Than $20K If You Live In This State

Equities

News

FFIE

GOEV

HYZN

KARS

LCID

NKLA

RIVN

TSLA

WKHS

XPEV

전기 자동차(EV) 주식은 더 넓은 시장의 긍정적인 성과에도 불구하고 9월 20일로 끝난 주를 엇갈린 분위기로 마감했다. 테슬라(NASDAQ:TSLA)는 몇 가지 긍정적인 요인으로 인해 7월 말 이후 최고 수준으로 상승했다.

주간 주요 EV 뉴스: 테슬라의 두 지역 이야기, 리비안이 R1 버전 출시, 니오는 온보 L60 출시 등

Lucid

Media

더 넓은 시장 강세는 전기 자동차(EV) 부문으로 확산되었고, 업계에 속한 대부분의 주식은 9월 13일로 끝난 주에 상당한 상승세를 기록했다. 그렇긴 하지만, 일부 신생 기업들은 지속적인 어려움을 반영하여 계속 적자를 면하지 못했다.

주간 주요 전기차 뉴스: 테슬라 중국의 성과, 루시드 중형 EV, 포드의 인도 재진출 계획 등

Analyst Color

GELYF

VLVCY

약한 경제 데이터 발표에 따른 시장 대혼란은 전기 자동차(EV) 주식을 아끼지 않았고 9월 6일로 끝나는 주 대부분이 하락세로 끝났다. 시장 선두주자인 테슬라(NASDAQ:TSLA)는 주중에 회복세를 보였음에도 불구하고 금요일의 고용 데이터로 인한 시장 매도세 속에서 상승폭을 반납했다.

주간 주요 전기차 뉴스: 테슬라의 야심찬 FSD 로드맵, 니오의 강력한 지침에 주가 급등 등

Citigroup analyst Yigal Nochomovitz upgrades Summit Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) from Neutral to Buy and raises the price target from $23 to $35.

Upgrades

Price Target

Analyst Ratings

SMMT

Citigroup Upgrades Summit Therapeutics to Buy, Raises Price Target to $35

Citigroup analyst Alastair Syme upgrades TotalEnergies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TTE#NYSE">TTE</a>) from Neutral to Buy.

Citigroup Upgrades TotalEnergies to Buy

JP Morgan analyst Jeffrey Zekauskas upgrades Ashland (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASH#NYSE">ASH</a>) from Neutral to Overweight and raises the price target from $68 to $71.

JP Morgan Upgrades Ashland to Overweight, Raises Price Target to $71

Matt Hougan, Chief Investment Officer at Bitwise Asset Management, declared that the final existential threat to Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) vanished with President Trump's recent executive order establishing a <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43889897/bitcoin-strategic-reserve-with-1-million-btc-could-offset-21-trillion-national-debt">U.S. Strategic Bitcoin Reserve</a>.
What Happened: In a note <a href="https://experts.bitwiseinvestments.com/cio-memos/the-great-derisking-of-bitcoin">released</a> on Tuesday, Hougan argued that this move eliminates the lingering fear of a government ban, marking the present as the safest time ever to invest in Bitcoin on a risk-adjusted basis.
Hougan traced Bitcoin's journey from its early days, recalling a 2011 meeting at ETF.com where it first hit $1—a moment he skipped investing in due to steep risks like shaky exchanges and regulatory uncertainty. 
"Back then, putting $1,000 into Bitcoin was a massive gamble," he wrote, citing issues like New Liberty Financial's sketchy setup and the lack of secure custody. 
Over time, he noted, Bitcoin overcame technical doubts, trading woes with Coinbase's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) rise, and custody fears as firms like Fidelity stepped in, steadily chipping away at its vulnerabilities.
The turning point, Hougan emphasized, came with Trump's order this month, which positions Bitcoin as a federal reserve asset using seized coins. 
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44486447/ripple-closes-in-on-legal-resolution-with-sec-will-recover-75-million-from-original-fine">Ripple Closes In On Legal Resolution With SEC, Will Recover $75 Million From Original Fine</a>
"The last existential risk I always mentioned at conferences was a U.S. ban—now it's gone," he stated, addressing past concerns about Bitcoin challenging the dollar. 
He argued the U.S. sees Bitcoin as a stronger fallback than rivals like China's yuan if the dollar's dominance wanes, a shift he didn't foresee earlier. 
This policy, he said, flips the script from potential suppression to strategic embrace.
Hougan pointed to shifting investor behavior as proof, noting Bitwise clients now often allocate 3% of portfolios to Bitcoin, up from 1% two years ago when a ban loomed as a possibility. 
What&#8217;s Next: He predicts this could climb to 5% or more as the market grasps Bitcoin's reduced risk profile, bolstered by spot Bitcoin ETFs launched in January 2024 and now this reserve.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44479576/digital-chamber-urges-congress-to-act-on-blockchain-for-national-security-financial-innovation-energy-independence">Digital Chamber Urges Congress To Act On Blockchain For National Security, Financial Innovation, Energy Independence</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

COIN

Strategic Bitcoin Reserve Eliminates Last Threat, Says Bitwise's Matt Hougan

Macro Economic Events

Global

Economics

China Issues Measures To Support Building Of International Consumption Centre Cities

DA Davidson analyst Michael Shlisky initiates coverage on Lakeland Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAKE#NASDAQ">LAKE</a>) with a Buy rating and announces Price Target of $28.

Initiation

LAKE

DA Davidson Initiates Coverage On Lakeland Industries with Buy Rating, Announces Price Target of $28

Earnings

Guidance

General

CHWY

Chewy Expects FY2025 Sales Of $12.30B-$12.45B, With Adj. EBITDA Margin Of 5.4%-7%

Chewy Expects Q1 FY2025 Sales Of $3.06B-$3.09B And Adj. EPS $0.30-$0.35 Versus Consensus Of $3.05B And $0.17, Respectively

China Renaissance analyst Guohan Wang downgrades Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) from Buy to Hold and announces $84 price target.

Downgrades

China Renaissance Downgrades Micron Technology to Hold, Announces $84 Price Target

Mereo BioPharma Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MREO#NASDAQ">MREO</a>) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(1.03) by 94.17 percent.

Earnings Beats

MREO

Mereo BioPharma Group Q4 2024 GAAP EPS $(0.06) Beats $(1.03) Estimate

NTLA

Intellia Therapeutics Announced That The U.S. Food And Drug Administration (Fda) Has Granted Regenerative Medicine Advanced Therapy (Rmat) Designation To Nexiguran Ziclumeran (Nex-z, Also Known As Ntla-2001) For The Treatment Of Transthyretin (Attr) Amyloidosis With Cardiomyopathy (Attr-cm)

Event to highlight the differentiated features of Traws oral small molecule product candidates:
<ul>
<li>Tivoxavir Marboxil, a single dose, CAP-dependent endonuclease inhibitor for Bird Flu</li>
<li>Ratutrelvir, a main protease inhibitor, to be used without ritonavir, for COVID-19</li>
</ul>

TRAW

Traws Pharma To Unveil Next-Gen Oral Antivirals for Bird Flu And COVID-19 At March 31 Investor Event

LAES

SEALSQ Finalizes Testing Of QS7001 Post-Quantum Secure Chip To Protect Blockchain And Crypto Wallets Ahead Of 2025 Launch

Kura Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KURA#NASDAQ">KURA</a>), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that an abstract containing preclinical data for KO-2806, the Company's next-generation farnesyl transferase inhibitor (FTI), in combination with cabozantinib, a tyrosine kinase inhibitor (TKI), in clear cell renal cell carcinoma (ccRCC), has been accepted for an oral presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting in Chicago, IL on April 29, 2025.

KURA

Kura Oncology to Present Kidney Cancer Drug Combo Data at AACR 2025

MAWSON INFRSTRUCTURE GRP by Mawson Infrastructure Group Inc.

MIGI

Mawson Infrastructure Announced That It Has Signed A Significant New Digital Colocation Customer Agreement With Canaan Inc

Biotech

Large Cap

Health Care

The European Commission Has Approved Merck's Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) For Active Immunization For The Prevention Of Invasive Disease And Pneumonia Caused By Streptococcus Pneumoniae Serotypes In Individuals 18 Years Of Age And Older

China Renaissance analyst Yiwen Zhang initiates coverage on Spotify Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) with a Buy rating and announces Price Target of $740.

SPOT

China Renaissance Initiates Coverage On Spotify Technology with Buy Rating, Announces Price Target of $740

REX American Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REX#NYSE">REX</a>) reported quarterly earnings of $0.63 per share which beat the analyst consensus estimate of $0.28 by 125 percent. This is a 45.69 percent decrease over earnings of $1.16 per share from the same period last year. The company reported quarterly sales of $158.20 million which beat the analyst consensus estimate of $151.54 million by 4.39 percent. This is a 15.68 percent decrease over sales of $187.61 million the same period last year.

REX American Resources Q4 2024 GAAP EPS $0.63 Beats $0.28 Estimate, Sales $158.20M Beat $151.54M Estimate

Wave Life Sciences Ltd.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced positive data from the Phase 2 FORWARD-53 trial of WVE-N531, which is an exon skipping oligonucleotide being investigated in boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 53 skipping. The analysis was conducted after 48 weeks of treatment with 10 mg/kg WVE-N531 dosed every two weeks (Q2W).
FORWARD-53 achieved all trial goals, demonstrating sustained and industry-leading exon skipping, muscle concentrations and dystrophin restoration through 48 weeks and a 61-day tissue half-life that supports monthly dosing. WVE-N531 continues to be safe and well-tolerated.
Additionally, the data demonstrate substantial decreases in inflammation and necrosis, a statistically significant reversal of muscle fibrosis (28.6% reduction between week 24 to 48; p&lt;0.01), and a transition from regeneration to maturation of muscle. A 50% decline (&lt;0.001) in creatine kinase (CK), as well as decreases in IL-6 and MCP-1, were also observed. Time-to-Rise (TTR) data demonstrate a statistically significant and clinically meaningful 3.8-second improvement versus natural history (p&lt;0.05), which is the largest effect observed relative to any approved dystrophin restoration therapy at 48 weeks. Additional functional benefits were observed on the North Star Ambulatory Assessment (NSAA) versus natural history, and in hand grip strength versus baseline.

Wave Life Sciences Reports Phase 2 DMD Trial Results With Dystrophin Restoration

Canaccord Genuity analyst Maria Ripps initiates coverage on Nexxen International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXN#NASDAQ">NEXN</a>) with a Buy rating and announces Price Target of $12.

NEXN

Canaccord Genuity Initiates Coverage On Nexxen International with Buy Rating, Announces Price Target of $12

Press Releases

Faraday Future's FX Brand to Ship First FX 6 Prototype Mules to U.S. Headquarters, Kicking Off the Product Development and Testing Phase

Faraday Future Hosts Event in New York City for Investment Bankers and Fund Managers, Presenting Latest Business Advancements with FF and the FX Brand

Faraday Future Announces the First Used 2023 FF 91 2.0 Closed at $235,000 on the Auction Site Bring a Trailer, an Impressive 76% Residual Value

Faraday Future Announces Plans to Expand its AI-Focused Recruitment as the Company Ramps Up its AI R&D Efforts in 2025

Faraday Future Announces the Shipment of Its First Two FX 6 Camouflaged Prototype Mules to the U.S.

Faraday Future Launches Global AI Innovation Competition, Inviting Interested Parties to Help Shape the Future of Mobility

Faraday Future Announces First Two FX 6 Camouflaged Prototype Mules Set to Depart Shanghai Today with Arrival into the Los Angeles Area in Mid-March

Faraday Future Announces 'FF Open AI Day' to Be Held on March 16 That Will Showcase the Company's Current and Future AI Strategy Developments

Faraday Future Announces New Ticker Symbol "FFAI"

Faraday Future Holds Special Meeting of Stockholders, Securing Stockholder Support for All Proposals

Faraday Future

Comments

(FFIE) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌